Tenofovir alafenamide, sold under the brand name Vemlidy, is an
antiviral medication used against
hepatitis B and
HIV. It is used for the treatment of
chronic hepatitis B virus (HBV) infection in adults with
compensated liver disease[8] and is given in combination with other medications for the prevention and treatment of HIV. It is taken
by mouth.[6]
Emtricitabine/tenofovir alafenamide (Descovy)[31] — approved in the United States in April 2016 (compare
emtricitabine/tenofovir; (Truvada)). In October 2019, Descovy was approved in the United States for HIV-1
pre-exposure prophylaxis (PrEP).[32][33]
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza)[35] — approved in the European Union in September 2017, in the United States in July 2018, and in Australia in November 2019.[36][37][38][39][40]
Gilead announced a
Phase III clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with
cobicistat,
emtricitabine and
elvitegravir[44] and developed a coformulation of the drug with cobicistat, emtricitabine and the
protease inhibitordarunavir.[45][46][47] In a 48-week study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild) to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya), the results showed the newer drug's effects to be non-inferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function.[48][49][50] The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015.[11] Genvoya is the first TAF-based regimen to receive approval.[11]
^Childs-Kean LM, Egelund EF, Jourjy J (October 2018). "Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection". Pharmacotherapy. 38 (10): 1051–1057.
doi:
10.1002/phar.2174.
PMID30120841.
S2CID52033420.
^Eisenberg EJ, He GX, Lee WA (2001). "Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood". Nucleosides Nucleotides Nucleic Acids. 20 (4–7): 1091–8.
doi:
10.1081/NCN-100002496.
PMID11562963.
S2CID24652157.
Tenofovir alafenamide, sold under the brand name Vemlidy, is an
antiviral medication used against
hepatitis B and
HIV. It is used for the treatment of
chronic hepatitis B virus (HBV) infection in adults with
compensated liver disease[8] and is given in combination with other medications for the prevention and treatment of HIV. It is taken
by mouth.[6]
Emtricitabine/tenofovir alafenamide (Descovy)[31] — approved in the United States in April 2016 (compare
emtricitabine/tenofovir; (Truvada)). In October 2019, Descovy was approved in the United States for HIV-1
pre-exposure prophylaxis (PrEP).[32][33]
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza)[35] — approved in the European Union in September 2017, in the United States in July 2018, and in Australia in November 2019.[36][37][38][39][40]
Gilead announced a
Phase III clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with
cobicistat,
emtricitabine and
elvitegravir[44] and developed a coformulation of the drug with cobicistat, emtricitabine and the
protease inhibitordarunavir.[45][46][47] In a 48-week study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild) to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya), the results showed the newer drug's effects to be non-inferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function.[48][49][50] The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015.[11] Genvoya is the first TAF-based regimen to receive approval.[11]
^Childs-Kean LM, Egelund EF, Jourjy J (October 2018). "Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection". Pharmacotherapy. 38 (10): 1051–1057.
doi:
10.1002/phar.2174.
PMID30120841.
S2CID52033420.
^Eisenberg EJ, He GX, Lee WA (2001). "Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood". Nucleosides Nucleotides Nucleic Acids. 20 (4–7): 1091–8.
doi:
10.1081/NCN-100002496.
PMID11562963.
S2CID24652157.